Eton Pharmaceuticals Inc
NASDAQ:ETON
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.06
11.23
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ETON stock under the Base Case scenario is 12.15 USD. Compared to the current market price of 11.23 USD, Eton Pharmaceuticals Inc is Undervalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eton Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ETON cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Eton Pharmaceuticals Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Eton Pharmaceuticals Inc
Balance Sheet Decomposition
Eton Pharmaceuticals Inc
Current Assets | 29.7m |
Cash & Short-Term Investments | 20.3m |
Receivables | 5.6m |
Other Current Assets | 3.9m |
Non-Current Assets | 6.1m |
PP&E | 226k |
Intangibles | 5.9m |
Other Non-Current Assets | 12k |
Current Liabilities | 19.7m |
Accounts Payable | 2.7m |
Accrued Liabilities | 12.9m |
Other Current Liabilities | 4.1m |
Non-Current Liabilities | 126k |
Other Non-Current Liabilities | 126k |
Earnings Waterfall
Eton Pharmaceuticals Inc
Revenue
|
34.7m
USD
|
Cost of Revenue
|
-14.1m
USD
|
Gross Profit
|
20.6m
USD
|
Operating Expenses
|
-25.8m
USD
|
Operating Income
|
-5.2m
USD
|
Other Expenses
|
-262k
USD
|
Net Income
|
-5.5m
USD
|
Free Cash Flow Analysis
Eton Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
ETON Profitability Score
Profitability Due Diligence
Eton Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Eton Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
ETON Solvency Score
Solvency Due Diligence
Eton Pharmaceuticals Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Eton Pharmaceuticals Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ETON Price Targets Summary
Eton Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ETON is 13.26 USD with a low forecast of 11.11 USD and a high forecast of 15.75 USD.
Dividends
Current shareholder yield for ETON is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ETON Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
Contact
IPO
Employees
Officers
The intrinsic value of one ETON stock under the Base Case scenario is 12.15 USD.
Compared to the current market price of 11.23 USD, Eton Pharmaceuticals Inc is Undervalued by 8%.